Parkinson's Disease: Bridging Gaps, Building Biomarkers and Reimagining Clinical Translation

Anjali Gahininath Kekan*, Miss.Reshma Dilip Pawar[1], Sunil Baban Rathod[2], Payal Subhash Ghode[3]
Sahakar Maharshi Kisanrao Varal Patil College of Pharmacy Nighoj (414306)

Abstract- Parkinson's disease (PD) represents one of the most challenging neurodegenerative disorders, characterized by progressive motor and non-motor symptoms that significantly impact quality of life. Despite decades of research, substantial gaps remain in early diagnosis, disease monitoring, and therapeutic development. This review examines the current landscape of PD biomarker research, highlighting advances in fluid-based, imaging, and digital biomarkers, while addressing the translational challenges that impede their clinical implementation. We discuss emerging technologies, including alpha-synuclein seed amplification assays, neuroimaging innovations, and multi-modal biomarker approaches that promise to revolutionize PD diagnosis and treatment. Furthermore, we explore the critical barriers to clinical translation and propose frameworks for accelerating the path from bench to bedside, emphasizing the need for standardization, validation, and patient-centered approaches in biomarker development.

Keywords: Parkinson's disease, biomarkers, alpha-synuclein, neuroimaging, clinical translation, precision medicine

I. INTRODUCTION

Parkinson's disease (PD) affects approximately 10 million people worldwide, with incidence rates projected to double by 2040 due to aging populations [1][2]. As the second most common neurodegenerative disorder after Alzheimer's disease, PD imposes substantial burdens on patients, families, and healthcare systems globally [3]. The cardinal motor features—bradykinesia, rigidity, tremor, and postural instability—emerge following extensive loss of dopaminergic neurons in the substantia nigra pars compacta, with an estimated 60-80% neuronal depletion at clinical diagnosis [4][5].

However, the prodromal phase of PD, characterized by non-motor symptoms such as hyposmia, REM sleep behavior disorder (RBD), and constipation, may precede motor manifestations by years or even decades [6][7]. This extended prodromal period represents a critical window for disease-modifying interventions, yet the absence of validated biomarkers for early detection and disease staging remains a fundamental limitation in PD research and clinical care [8][9].

The development and validation of robust biomarkers constitute essential prerequisites for advancing PD therapeutics. Biomarkers serve multiple critical functions: enabling early and accurate diagnosis, monitoring disease progression, stratifying patients for clinical trials, predicting therapeutic response, and serving as surrogate endpoints for disease modification [10]. Despite significant progress in understanding PD pathophysiology, the field has struggled to translate biological insights into clinically useful biomarkers [11].

This review synthesizes current knowledge regarding PD biomarker development across multiple modalities, examines the translational challenges hindering clinical implementation, and proposes strategies for bridging the gap between discovery and clinical utility. We focus on three primary domains: fluid-based biomarkers, neuroimaging biomarkers, and digital/wearable technology-based biomarkers, while addressing the critical need for multi-modal integration and standardized validation frameworks [12].

II. THE BIOMARKER GAP IN PARKINSON'S DISEASE

Current Diagnostic Limitations

PD diagnosis remains predominantly clinical, relying on the identification of motor symptoms according to established criteria such as the Movement Disorder Society (MDS) clinical diagnostic criteria[13]. This approach suffers from several limitations: moderate diagnostic accuracy, particularly in early disease stages; inability to detect prodromal PD; poor differentiation from atypical parkinsonian syndromes; and lack of

objective measures for disease progression [14][15]. Autopsy studies reveal diagnostic error rates of 10-25% even among movement disorder specialists, highlighting the urgent need for objective diagnostic tools [16].

The Prodromal Challenge

Emerging evidence suggests that PD pathology begins decades before motor symptom onset, offering a potential therapeutic window that remains largely unexploited due to the absence of reliable early detection methods [17][18]. The MDS has proposed research criteria for prodromal PD, incorporating clinical features and biomarkers to estimate the probability of developing clinical PD. However, implementation of these criteria in clinical practice remains limited by the lack of validated, accessible biomarkers[19].

Heterogeneity and Subtypes

PD exhibits remarkable clinical and pathological heterogeneity, with variations in age of onset, symptom predominance, progression rates, and treatment responses [20][21]. Recent efforts to define PD subtypes based on clinical, genetic, and biomarker profiles aim to enable precision medicine approaches [22]. However, successful subtyping requires robust biomarkers that capture underlying pathobiological mechanisms rather than merely describing clinical phenotypes[23].

Fluid-Based Biomarkers: From Discovery to Validation

Alpha-Synuclein: The Central Player

Alpha-synuclein (α-syn) pathology, manifesting as Lewy bodies and Lewy neurites, represents the pathological hallmark of PD [24]. Consequently, α-syn has been the focus of intensive biomarker research. However, early studies measuring total or phosphorylated α-syn in cerebrospinal fluid (CSF) yielded inconsistent results, with modest decreases observed in PD patients compared to controls [25][26].

Seed Amplification Assays: A Breakthrough

The development of protein misfolding seed amplification assays, including real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA), represents a paradigm shift in α-syn biomarker research [27][28]. These techniques detect minute quantities of misfolded α-syn seeds in CSF, achieving sensitivities of 85-95% and specificities of 90-100% for distinguishing PD from controls and atypical parkinsonian disorders [29][30].



Fig.1. Pathogenic Mechanisms Leading to Dopaminergic Neuron Degenaration in Parkinson's Disease

Remarkably, α-syn seed amplification assays have demonstrated the ability to detect pathological α-syn in peripheral tissues, including skin biopsies and submandibular gland tissue, offering less invasive diagnostic options [31][32].

The α-syn-SAA has shown promise in identifying individuals at risk during the prodromal phase, with positive results in patients with isolated RBD years before motor symptom onset [33].

Neurofilament Light Chain

Neurofilament light chain (NfL) has emerged as a promising biomarker of neurodegeneration across multiple neurological disorders [34]. In PD, elevated NfL levels in CSF and blood correlate with disease severity and progression rates, potentially serving as a prognostic marker[35][36]. Importantly, ultra-sensitive single-molecule array (Simoa) technology enables reliable NfL measurement in blood, circumventing the need for invasive CSF collection [37].

Multi-Marker Panels

Recognition of PD's multifaceted pathophysiology has driven efforts to develop multi-marker panels incorporating α-syn species, inflammatory markers, oxidative stress indicators, and markers of synaptic dysfunction [38][39]. The Parkinson's Progression Markers Initiative (PPMI) and other large-scale studies have systematically evaluated candidate biomarkers, revealing that combinations of markers may achieve superior diagnostic and prognostic performance compared to individual biomarkers [40][41].

Extracellular Vesicles and Exosomes

Extracellular vesicles (EVs), particularly neuronal-derived exosomes, offer a novel approach to accessing CNS-derived biomarkers from peripheral blood [42]. Enriched exosomal fractions can be isolated and analyzed for α-syn, tau, and other proteins, potentially providing a "liquid biopsy" of brain pathology [43]. However, methodological challenges in EV isolation and characterization must be addressed before clinical translation.[44]

Neuroimaging Biomarkers: Visualizing Pathology

Dopaminergic Imaging

Dopamine transporter (DAT) imaging using single-photon emission computed tomography (SPECT) or positron emission tomography (PET) provides objective visualization of nigrostriatal dopaminergic degeneration [45]. DAT imaging demonstrates high accuracy for distinguishing PD from essential tremor and other non-degenerative conditions, leading to regulatory approval for clinical use [46][47]. However, DAT imaging cannot reliably differentiate PD from atypical parkinsonian syndromes, which also exhibit dopaminergic deficits [48].

Neuromelanin-Sensitive MRI

Neuromelanin-sensitive MRI (NM-MRI) enables visualization of neuromelanin content in the substantia nigra, which decreases in PD due to dopaminergic neuronal loss [49]. NM-MRI offers advantages of non-invasiveness, absence of radioactivity, and wide availability of MRI scanners [50]. Recent advances in automated quantification methods and ultra-high-field MRI have improved sensitivity, with studies demonstrating potential for detecting prodromal PD [51].

Advanced Structural MRI

Diffusion tensor imaging (DTI), volumetric analysis, and other advanced MRI techniques have revealed subtle structural changes in PD affecting the substantia nigra, basal ganglia, and cortical regions [52][53]. While individual structural MRI measures show limited diagnostic utility, machine learning approaches integrating multiple imaging features demonstrate promising classification accuracies [54][55].

Functional and Metabolic Imaging

Fluorodeoxyglucose (FDG) PET imaging reveals characteristic patterns of altered glucose metabolism in PD, with specific metabolic brain networks associated with motor symptoms, cognitive decline, and disease progression [56][57]. Resting-state functional MRI (rs-fMRI) has identified disrupted functional connectivity in PD, particularly involving the default mode network, sensorimotor network, and basal ganglia circuits [58][59].

Alpha-Synuclein PET Tracers

Development of PET tracers capable of binding pathological α-syn aggregates represents a major research priority, analogous to amyloid PET in Alzheimer's disease [60]. Several candidate tracers are in early development, though challenges in achieving sufficient specificity and selectivity for α-syn over other aggregated proteins remain [61][61].

Digital and Wearable Technology Biomarkers

Quantitative Motor Assessment

Traditional clinical motor assessment relies on subjective rating scales such as the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), which suffer from inter-rater variability, snapshot nature, and insensitivity to subtle changes [63]. Digital technologies, including wearable sensors, smartphone applications, and home monitoring

systems, enable continuous, objective quantification of motor symptoms in real-world environments [64][65].

Accelerometers and gyroscopes can quantify tremor amplitude and frequency, gait parameters, bradykinesia severity, and dyskinesia [66][67]. Smartphone-based tasks assessing finger tapping, voice, and gait have demonstrated correlations with clinical severity and potential for detecting early motor changes [68][69].

Gait and Balance Analysis

Gait impairment represents a core feature of PD with significant impact on falls and quality of life. Instrumented gait analysis using wearable sensors provides detailed characterization of spatiotemporal gait parameters, asymmetry, variability, and dual-task interference [70][71]. Specific gait signatures have been associated with freezing of gait and fall risk, potentially enabling proactive intervention [72].

Passive Monitoring and Real-World Data

Passive monitoring using smartwatches and activity trackers captures real-world physical activity, sleep patterns, and circadian rhythms without requiring active patient engagement [73][74]. These measures provide ecologically valid assessments of functional capacity and may serve as endpoints in clinical trials [75].

Voice and Speech Analysis

Voice and speech alterations occur early in PD and progress throughout the disease course [76]. Acoustic analysis of voice recordings can quantify parameters including fundamental frequency, jitter, shimmer, and articulation rate [77]. Machine learning algorithms applied to speech recordings have achieved diagnostic accuracies exceeding 85% in some studies [78][79].

Genetic Biomarkers and Precision Medicine

Approximately 10-15% of PD cases have a clear genetic cause, with pathogenic variants identified in genes including SNCA, LRRK2, PARK7, PINK1, PRKN, and VPS35 [80].



Fig.2. Multimodal biomarker landscape enabling precision diagnosis in Parkinson’s disease

Genetic testing informs prognosis, familial risk, and increasingly, therapeutic stratification[81]. LRRK2 inhibitors are in clinical development specifically for LRRK2 mutation carriers, exemplifying precision medicine in PD [82].

Genome-wide association studies (GWAS) have identified over 90 genetic risk loci for PD, illuminating pathways including lysosomal function, immune response, and α-syn regulation [83][84]. Polygenic risk scores integrating multiple genetic variants may enable risk stratification and early identification of at-risk individuals, though clinical implementation remains investigational [85].

Multi-Modal Integration and Systems Approaches

Recognition that no single biomarker adequately captures PD's complexity has driven efforts toward multi-modal integration [86]. Machine learning and artificial intelligence approaches can integrate diverse data types—genetic, fluid biomarkers, imaging, clinical, and digital—to develop comprehensive disease signatures [87][88].

The PPMI exemplifies this integrative approach, longitudinally collecting extensive multi-modal data in a well-characterized cohort [89]. Analysis of PPMI data has revealed that combinations of biomarkers achieve superior predictive performance for progression and phenotype compared to individual markers [90].

Systems biology approaches modeling the interactions between molecular pathways, genetic factors, and environmental exposures offer potential for mechanistic understanding and biomarker discovery [91]. These approaches may identify novel biomarkers reflecting specific pathobiological processes amenable to targeted therapeutic intervention [92].

Clinical Translation: Barriers and Solutions

Standardization and Harmonization

A critical barrier to biomarker translation is the lack of standardization in sample collection, processing, analysis, and interpretation [93]. Pre-analytical variables significantly impact biomarker measurements, necessitating standardized operating procedures across research sites and clinical laboratories [94]. International consortia such as the Michael J. Fox Foundation and the Parkinson Study Group are working toward harmonizing protocols and establishing reference standards [95].

Analytical Validation

Rigorous analytical validation is essential before clinical implementation. Biomarkers must demonstrate acceptable precision, accuracy, sensitivity, specificity, and reproducibility across different laboratories and platforms [96]. For α-syn seed amplification assays, inter-laboratory validation studies have shown promising reproducibility, though challenges remain in assay optimization and quality control [97].

Clinical Qualification

Beyond analytical validation, biomarkers require clinical qualification demonstrating fitness for specific contexts of use [98]. The regulatory framework distinguishes between exploratory biomarkers, probable valid biomarkers, and known valid biomarkers based on the strength of supporting evidence [99]. Progressing biomarkers through these stages requires substantial investment in well-designed longitudinal studies with appropriate clinical endpoints [100].

Accessibility and Cost

Even validated biomarkers may face implementation barriers if they are prohibitively expensive, require specialized equipment, or involve invasive procedures [101]. Blood-based biomarkers offer advantages in accessibility compared to CSF or advanced neuroimaging, though development of point-of-care testing platforms remains a priority [102]. Digital biomarkers collected via consumer devices represent the most scalable approach, though data quality and privacy concerns must be addressed [103].

Regulatory Pathways

Navigating regulatory approval processes for biomarker tests represents a significant translational hurdle [104]. In the United States, the FDA provides guidance for biomarker qualification through the Biomarker Qualification Program, while in Europe, the EMA offers scientific advice procedures [105]. Engagement with regulatory agencies early in biomarker development facilitates efficient translation.

Clinical Utility and Implementation

Demonstrating clinical utility—that biomarker use improves patient outcomes—represents the ultimate translational challenge [106]. Cost-effectiveness analyses, implementation studies, and education of clinicians are necessary for successful adoption into

clinical practice. The experience with DAT imaging illustrates both the potential and challenges of biomarker implementation in PD [107].

Future Directions and Emerging Paradigms

Precision Medicine and Disease Subtypes

The future of PD management lies in precision medicine approaches that match specific interventions to individual patient characteristics [108]. Defining biologically-based disease subtypes using integrated biomarker profiles will enable targeted therapeutic development and personalized treatment selection [109].

Prodromal and Preventive Strategies

As disease-modifying therapies emerge, focus will shift toward prodromal intervention and prevention [110]. Biomarker-based risk stratification combined with genetic and clinical risk factors will identify candidates for preventive trials [111]. Ethical considerations surrounding predictive testing and preventive intervention in asymptomatic individuals require careful attention [112].

Target Engagement and Pharmacodynamic Biomarkers

Development of disease-modifying therapies requires biomarkers demonstrating target engagement and pharmacodynamic effects [113]. For α-syn-directed therapies, measures of α-syn aggregation, propagation, and clearance serve as critical pharmacodynamic endpoints [114]. Establishing such biomarkers will accelerate drug development by enabling early go/no-go decisions [115].

Artificial Intelligence and Big Data

Machine learning and artificial intelligence hold enormous potential for biomarker discovery, pattern recognition, and predictive modeling [116]. Deep learning applied to neuroimaging can identify subtle patterns invisible to human observers, while natural language processing of clinical notes may extract prognostic information [117][118]. However, ensuring algorithmic fairness, transparency, and generalizability across diverse populations remains essential [119].

Participatory Research and Patient Engagement

Meaningful patient engagement in biomarker research ensures that development priorities align with patient needs and values [120]. Patient registries, online cohorts, and citizen science initiatives democratize research participation and accelerate recruitment [121]. The Fox Insight study exemplifies how online platforms can engage thousands of participants in biomarker research [122].

III.CONCLUSIONS

Parkinson's disease biomarker research has achieved remarkable progress, with α-synuclein seed amplification assays, advanced neuroimaging, and digital technologies offering unprecedented opportunities for early diagnosis, progression monitoring, and therapeutic development. However, substantial gaps persist between biomarker discovery and clinical implementation.

Bridging these gaps requires coordinated efforts across multiple domains: rigorous analytical and clinical validation; standardization of methodologies; demonstration of clinical utility; regulatory engagement; and consideration of accessibility and cost. Multi-modal integration combining complementary biomarker types promises to capture PD's complexity more comprehensively than individual markers.

Reimagining clinical translation in PD necessitates embracing precision medicine paradigms, shifting focus toward prodromal intervention, developing pharmacodynamic biomarkers for drug development, harnessing artificial intelligence, and meaningfully engaging patients as partners in research. As the PD community confronts these challenges collectively, the vision of biomarker-guided personalized care for all individuals affected by PD moves closer to reality.

The convergence of technological innovation, collaborative research infrastructure, and mechanistic understanding positions the field at a transformative moment. Realizing the promise of biomarkers to revolutionize PD diagnosis and treatment will require sustained commitment, adequate resources, and unwavering focus on translating scientific discoveries into tangible benefits for patients and families facing this challenging disease.

REFERENCES

[1] Dorsey ER, Bloem BR. The Parkinson pandemic-A call to action. JAMA Neurol. 2018;75(1):9-10.

[2] GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939-953.
[3] Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov Disord. 2013;28(3):311-318.
[4] Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013;136(Pt 8):2419-2431.
[5] Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010;67(6):715-725.
[6] Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-1601.
[7] Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2015;30(12):1600-1611.
[8] Siderowf A, Lang AE. Premotor Parkinson's disease: concepts and definitions. Mov Disord. 2012;27(5):608-616.
[9] Marek K, Jennings D, Lasch S, et al. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol. 2011;95(4):629-635.
[10] Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95.
[11] Merchant KM, Simuni T, Fedler J, Brundin P. Pilot studies and clinical trial planning in Parkinson's disease: time to prioritize the development of precision medicine. Mov Disord. 2020;35(4):577-581.
[12] Parnetti L, Gaetani L, Eusebi P, et al. CSF and blood biomarkers for Parkinson's disease. Lancet Neurol. 2019;18(6):573-586.
[13] Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-1601.
[14] Rizzo G, Copetti M, Arcuti S, et al. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;86(6):566-576.
[15] Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology. 2014;83(5):406-412.
[16] Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125(Pt 4):861-870.
[17] Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211.
[18] Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord. 2010;16(2):79-84.
[19] Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2015;30(12):1600-1611.
[20] Fereshtehnejad SM, Romenets SR, Anang JB, et al. New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol. 2015;72(8):863-873.
[21] Marras C, Lang A. Parkinson's disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry. 2013;84(4):409-415.
[22] Espay AJ, Schwarzschild MA, Tanner CM, et al. Biomarker-driven phenotyping in Parkinson's disease: a translational missing link in disease-modifying clinical trials. Mov Disord. 2017;32(3):319-324.
[23] Greenland JC, Williams-Gray CH, Barker RA. The clinical heterogeneity of Parkinson's disease and its therapeutic implications. Eur J Neurosci. 2019;49(3):328-338.
[24] Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839-840.
[25] Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10(3):230-240.
[26] Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun. 2006;349(1):162-166.
[27] Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3(10):812-818.
[28] Saijo E, Ghetti B, Zanusso G, et al. Ultrasensitive and selective detection of 3-repeat tau seeding activity in Pick disease brain

and cerebrospinal fluid. Acta Neuropathol. 2017;133(5):751-765.

[29] Garrido A, Fairfoul G, Tolosa ES, et al. α-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson's disease. Ann Clin Transl Neurol. 2019;6(6):1024-1032.

[30] Iranzo A, Fairfoul G, Ayudhaya ACN, et al. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 2021;20(3):203-212.

[31] Manne S, Kondru N, Jin H, et al. α-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson's disease patients. Mov Disord. 2020;35(2):268-278.

[32] Wang Z, Becker K, Donadio V, et al. Skin α-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol. 2021;78(1):30-40.

[33] Iranzo A, Fairfoul G, Ayudhaya ACN, et al. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 2021;20(3):203-212.

[34] Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577-589.

[35] Hansson O, Janelidze S, Hall S, et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017;88(10):930-937.

[36] Lin CH, Li CH, Yang KC, et al. Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology. 2019;93(11):e1104-e1111.

[37] Gaetani L, Blennow K, Calabresi P, et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870-881.

[38] Henchcliffe C, Shungu DC, Mao X, et al. Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial dysfunction in Parkinson's disease. Ann N Y Acad Sci. 2008;1147:206-220.

[39] Magdalinou NK, Paterson RW, Schott JM, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015;86(11):1240-1247.

[40] Kang JH, Mollenhauer B, Coffey CS, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Acta Neuropathol. 2016;131(6):935-949.

[41] Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75(12):1055-1061.

[42] Rani K, Mukherjee R, Singh E, et al. Neuronal exosomes in saliva of Parkinson's disease patients: a pilot study. Parkinsonism Relat Disord. 2019;67:21-23.

[43] Shi M, Liu C, Cook TJ, et al. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta Neuropathol. 2014;128(5):639-650.

[44] Kluge A, Bunk J, Schaeffer E, et al. Detection of neuron-derived pathological α-synuclein in blood. Brain. 2022;145(9):3058-3071.

[45] Kägi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81(1):5-12.

[46] Suwijn SR, van Boheemen CJ, de Haan RJ, et al. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review. EJNMMI Res. 2015;5(1):12.

[47] Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021;20(5):385-397.

[48] Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2013;84(11):1288-1295.

[49] Sasaki M, Shibata E, Tohyama K, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport. 2006;17(11):1215-1218.

[50] Huddleston DE, Langley J, Sedlacik J, et al. In vivo detection of lateral-ventral tier nigral degeneration in Parkinson's disease. Hum Brain Mapp. 2017;38(5):2627-2634.

[51] Langley J, Huddleston DE, Chen X, et al. A multicontrast approach for comprehensive imaging of substantia nigra. Neuroimage. 2015;112:7-13.

[52] Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology. 2009;72(16):1378-1384.
[53] Cochrane CJ, Ebmeier KP. Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology. 2013;80(9):857-864.
[54] Heim B, Krismer F, De Marzi R, Seppi K. Magnetic resonance imaging for the diagnosis of Parkinson's disease. J Neural Transm (Vienna). 2017;124(8):915-964.
[55] Lei H, Zhao W, Chen Y, et al. Machine learning-based multimodal neuroimaging for the diagnosis of Parkinson's disease: a meta-analysis. Neurosci Biobehav Rev. 2021;129:280-292.
[56] Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci. 2009;32(10):548-557.
[57] Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain. 2007;130(Pt 7):1834-1846.
[58] Göttlich M, Münte TF, Heldmann M, et al. Altered resting state brain networks in Parkinson's disease. PLoS One. 2013;8(10):e77336.
[59] Krajcovicova L, Mikl M, Marecek R, Rektorova I. The default mode network integrity in patients with Parkinson's disease is levodopa equivalent dose-dependent. J Neural Transm (Vienna). 2012;119(4):443-454.
[60] Kotzbauer PT, Tu Z, Mach RH. Current status of the development of PET radiotracers for imaging alpha synuclein aggregates in Lewy bodies and Lewy neurites. Clin Transl Imaging. 2017;5(1):3-14.
[61] Verdurand M, Levigoureux E, Zeinyeh W, et al. In silico, in vitro, and in vivo evaluation of new candidates for α-synuclein PET imaging. Mol Pharm. 2018;15(8):3153-3166.
[62] Bagchi DP, Yu L, Perlmutter JS, et al. Binding of the radioligand SIL23 to α-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS One. 2013;8(2):e55031.
[63] Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-2170.
[64] Espay AJ, Bonato P, Nahab FB, et al. Technology in Parkinson's disease: challenges and opportunities. Mov Disord. 2016;31(9):1272-1282.
[65] Maetzler W, Domingos J, Srulijes K, et al. Quantitative wearable sensors for objective assessment of Parkinson's disease. Mov Disord. 2013;28(12):1628-1637.
[66] Del Din S, Godfrey A, Mazzà C, et al. Free-living monitoring of Parkinson's disease: lessons from the field. Mov Disord. 2016;31(9):1293-1313.
[67] Griffiths RI, Kotschet K, Arfon S, et al. Automated assessment of bradykinesia and dyskinesia in Parkinson's disease. J Parkinsons Dis. 2012;2(1):47-55.
[68] Arora S, Venkataraman V, Zhan A, et al. Detecting and monitoring the symptoms of Parkinson's disease using smartphones: a pilot study. Parkinsonism Relat Disord. 2015;21(6):650-653.
[69] Bot BM, Suver C, Neto EC, et al. The mPower study, Parkinson disease mobile data collected using ResearchKit. Sci Data. 2016;3:160011.
[70] Hubble RP, Naughton GA, Silburn PA, Cole MH. Wearable sensor use for assessing standing balance and walking stability in people with Parkinson's disease: a systematic review. PLoS One. 2015;10(4):e0123705.
[71] Del Din S, Godfrey A, Galna B, et al. Free-living gait characteristics in ageing and Parkinson's disease: impact of environment and ambulatory bout length. J Neuroeng Rehabil. 2016;13(1):46.
[72] Mancini M, Carlson-Kuhta P, Zampieri C, et al. Postural sway as a marker of progression in Parkinson's disease: a pilot longitudinal study. Gait Posture. 2012;36(3):471-476.
[73] Rovini E, Maremmani C, Cavallo F. How wearable sensors can support Parkinson's disease diagnosis and treatment: a systematic review. Front Neurosci. 2017;11:555.
[74] Lonini L, Dai A, Shawen N, et al. Wearable sensors for Parkinson's disease: which data are worth collecting for training symptom detection models. NPJ Digit Med. 2018;1:64.
[75] Bloem BR, Dorsey ER, Okun MS. The coronavirus disease 2019 crisis as catalyst for

telemedicine for chronic neurological disorders. JAMA Neurol. 2020;77(8):927-928.

[76] Skodda S, Grönheit W, Schlegel U. Impairment of vowel articulation as a possible marker of disease progression in Parkinson's disease. PLoS One. 2012;7(2):e32132.

[77] Tsanas A, Little MA, McSharry PE, et al. Novel speech signal processing algorithms for high-accuracy classification of Parkinson's disease. IEEE Trans Biomed Eng. 2012;59(5):1264-1271.

[78] Rusz J, Cmejla R, Tykalova T, et al. Imprecise vowel articulation as a potential early marker of Parkinson's disease: effect of speaking task. J Acoust Soc Am. 2013;134(3):2171-2181.

[79] Vaiciukynas E, Verikas A, Gelzinis A, et al. Detecting Parkinson's disease from sustained phonation and speech signals. PLoS One. 2017;12(10):e0185613.

[80] Bandres-Ciga S, Diez-Fairen M, Kim JJ, Singleton AB. Genetics of Parkinson's disease: an introspection of its journey towards precision medicine. Neurobiol Dis. 2020;137:104782.

[81] Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson's disease. Lancet Neurol. 2020;19(2):170-178.

[82] Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol. 2020;16(2):97-107.

[83] Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091-1102.

[84] Chang D, Nalls MA, Hallgrímsdóttir IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat Genet. 2017;49(10):1511-1516.

[85] Paul KC, Schulz J, Bronstein JM, et al. Association of polygenic risk score with cognitive decline and motor progression in Parkinson disease. JAMA Neurol. 2018;75(3):360-366.

[86] Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Brain. 2017;140(7):1959-1976.

[87] Laansma MA, Bright JK, Al-Bachari S, et al. International multicenter analysis of brain structure across clinical stages of Parkinson's disease: MDS-PPMI Neuroimaging Study. Neurology. 2021;97(23):e2191-e2203.

[88] Hett K, Ta D, Catheline G, et al. Multimodal hippocampal subfield grading for Alzheimer's disease classification. Sci Rep. 2021;11(1):13845.

[89] Marek K, Chowdhury S, Siderowf A, et al. The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. Ann Clin Transl Neurol. 2018;5(12):1460-1477.

[90] Latourelle JC, Beste MT, Hadzi TC, et al. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation. Lancet Neurol. 2017;16(11):908-916.

[91] Santiago JA, Potashkin JA. System-based approaches to decode the molecular links in Parkinson's disease and diabetes. Neurobiol Dis. 2014;72 Pt A:84-91.

[92] Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912.

[93] Mollenhauer B, Trautmann E, Taylor P, et al. Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett. 2013;532:44-48.

[94] Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73(22):1914-1922.

[95] Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178-190.

[96] Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res. 2006;23(2):312-328.

[97] Rossi M, Candelise N, Baiardi S, et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 2020;140(1):49-62.

[98] FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); 2016.

[99] Amur S, Frueh FW, Lesko LJ, Huang SM. Integration and use of biomarkers in drug

development, regulation and clinical practice: a US regulatory perspective. Biomark Med. 2008;2(3):305-311.

[100] Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407-417.

[101] Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016;537(7618):50-56.

[102] Sabbagh MN, Lue LF, Fayard D, Shi J. Increasing precision of clinical diagnosis of Alzheimer's disease using a combined algorithm incorporating clinical and novel biomarker data. Neurol Ther. 2017;6(Suppl 1):83-95.

[103] Dorsey ER, Papapetropoulos S, Xiong M, Kieburtz K. The first frontier: digital biomarkers for neurodegenerative disorders. Digit Biomark. 2017;1(1):6-13.

[104] Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood). 2018;243(3):213-221.

[105] EMA. Qualification opinion on IMI EPAD low hippocampal volume (atrophy) biomarker qualification. 2019.

[106] Bossuyt PM, Reitsma JB, Linnet K, Moons KG. Beyond diagnostic accuracy: the clinical utility of diagnostic tests. Clin Chem. 2012;58(12):1636-1643.

[107] Ferrante J. Principles of test selection and use. Clin Lab Med. 2002;22(2):457-478.

[108] Espay AJ, Brundin P, Lang AE. Precision medicine for disease modification in Parkinson disease. Nat Rev Neurol. 2017;13(2):119-126.

[109] Fereshtehnejad SM. Strategies to maintain clinical trial participation and retention in Parkinson's disease. J Parkinsons Dis. 2016;6(4):623-633.

[110] Simuni T, Uribe L, Cho HR, et al. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurol. 2020;19(1):71-80.

[111] Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019;142(3):744-759.

[112] Schermer MH, Richard E. On the reconceptualization of Alzheimer's disease. Bioethics. 2019;33(1):138-145.

[113] Morgan P, Brown DG, Lennard S, et al. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discov. 2018;17(3):167-181.

[114] Pagano G, Taylor KI, Anzures-Cabrera J, et al. Trial of prasinezumab in early-stage Parkinson's disease. N Engl J Med. 2022;387(5):421-432.

[115] Cook D, Brown D, Alexander R, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13(6):419-431.

[116] Camacho M, Wilms H, Geisslinger G, et al. Machine learning and deep learning in neuroimaging data analysis for Parkinson's disease: a systematic review. Comput Biol Med. 2023;164:107286.

[117] Eshaghi A, Young AL, Wijeratne PA, et al. Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. Nat Commun. 2021;12(1):2078.

[118] Ravi D, Wong C, Deligianni F, et al. Deep learning for health informatics. IEEE J Biomed Health Inform. 2017;21(1):4-21.

[119] Rajkomar A, Hardt M, Howell MD, et al. Ensuring fairness in machine learning to advance health equity. Ann Intern Med. 2018;169(12):866-872.

[120] Frank L, Basch E, Selby JV. The PCORI perspective on patient-centered outcomes research. JAMA. 2014;312(15):1513-1514.

[121] Dorsey ER, Yvonne Chan YF, McConnell MV, et al. The use of smartphones for health research. Acad Med. 2017;92(2):157-160.

[122] Smolensky L, Amondikar N, Crawford K, et al. Fox Insight collects online, longitudinal patient-reported outcomes and genetic data on Parkinson's disease. Sci Data. 2020;7(1):67.